United Therapeutics Posts Data From Remodulin Induction Before Orenitram Therapy In High Blood Pressure Patients

United Therapeutics Corp UTHR announced a preliminary analysis of the EXPEDITE Phase 4 16-week study of Remodulin induction followed by oral Orenitram optimization in patients with pulmonary arterial hypertension (PAH).
The data demonstrated that 79% of patients in the study reached the study's primary endpoint of a 12 mg total daily dose after an up to eight-week induction treatment period with Remodulin (treprostinil) injection.
Also See: United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease.
A short induction of Remodulin (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram (treprostinil) extended-release tablets than patients who did not have a Remodulin induction.
A previous real-world dosing analysis showed an average Orenitram dose of approximately 6 mg daily after 16 weeks without the induction protocol studied by the EXPEDITE study.
In addition, scientific literature shows that higher doses of treprostinil have been associated with better outcomes for PAH patients.
Treatment with Orenitram, three times daily, was well tolerated, and the safety profile was consistent with previous Orenitram studies in PAH.
Price Action: UTHR shares traded lower by 1.37% at $228.98 on the last check Monday.